Page 231 - HIVMED_v21_i1.indb

Page 4 of 11 Review Article

Strength/weakness of design The data were collected from various field experts, comprising HIV clinicians, researchers, country HIV programme managers, guideline methodologists, partners from the United Nations or other development agencies and nominated representatives of civil society and/or networks of people living with HIV (selected on the basis of four criteria: technical knowledge, constituency and regional representation, previous experience with guidelines developm

Major outcomes of study The findings of these community consultations have reinforced the importance of community representation, involvement, and participation in normative guidelines development. For the effective scale-up of ART programmes, it is critical to have a nuanced appreciation for the different ways in which people interact with certain services, and the role of communities and civil society in service delivery. Mortality risk and risk for AIDS appear to be

Study location Malawi and Uganda. South Africa, Zambia, Angola, Kenya, Uganda, Lesotho and Nigeria 43 Sub-Saharan African countries Kenya, Uganda and Zambia.

Study focus The study focused on evaluating community and HCW values and preferences on key topics to inform the development of the 2013 WHO consolidated guidelines for antiretroviral therapy in low- and middle-income countries. Clinical outcomes and benefits of early ART initiation at CD4 cell count 500 and below. Questionnaires were sent to countries identified by WHO as requiring special attention for developing HIV-therapeutic and preventive health services

Type of study Cross- sectional e-survey and e-forum discussion, FGDs Observational Study Observational Study Observational analysis.

Study objectives The study assessed adaptation and implementation of the 2013 WHO guidelines at country level and suggests how to optimise community engagement to inform future guidelines. The study assessed differences in clinical benefits between individuals starting treatment at CD4 counts ≥ 500 cells/mm 3 (early initiation) as compared with < 500 cells/mm 3 (deferred initiation). The study investigated the existence of national ART guidelines in S

TABLE 1 (Continues...): Summary of studies. Theme identified Guidelines year Timely implementation of 2013 WHO and ART initiation policy guidelines at country level Adoption of WHO and ART initiation policy guidelines at national level Barriers and facilitators to WHO-policy implementation Adoption of WHO and ART 2015 initiation policy guidelines at national level Barriers and facilitators to WHO-policy implementation Timely implementation of 2002 WHO and ART init

Song et al. 16
Hsieh et al. 6
Beck et al. 3
and year
Author
Paper 5
Paper 6
Paper 4
2006
2014
2018
http://www.sajhivmed.org.za 223 Open Access Duber et al. 17 2015 Paper 7